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Abstract
An association between periodontitis and nonalcoholic fatty liver disease (NAFLD) has been reported by experimental animal and 
epidemiologic studies. This study investigated whether circulating levels of serum C-reactive protein (CRP) and a weighted genetic CRP 
score representing markers of inflammatory burden modify the association between periodontitis and NAFLD. Data came from 2,481 
participants of the Study of Health in Pomerania who attended baseline examination that occurred between 1997 and 2001. Periodontitis 
was defined as the percentage of sites (0%, <30%, ≥30%) with probing pocket depth (PD) ≥4 mm, and NAFLD status was determined using 
liver ultrasound assessment. Serum CRP levels were assayed at a central laboratory, and single-nucleotide polymorphisms previously 
identified through genome-wide association studies as robustly associated with serum CRP were combined into a weighted genetic CRP 
score (wGSCRP). Logistic regression models estimated the association between periodontitis and NAFLD within strata of serum CRP and 
separately within strata of the wGSCRP. The prevalence of NAFLD was 26.4% (95% confidence interval [CI], 24.6, 28.1) while 17.8% (95% 
CI, 16.0–19.6) had ≥30% of sites with PD ≥4 mm. Whereas the wGSCRP was not a modifier (Pinteraction = 0.8) on the multiplicative scale, 
serum CRP modified the relationship between periodontitis and NAFLD (Pinteraction = 0.01). The covariate-adjusted prevalence odds ratio 
of NAFLD comparing participants with ≥30% of sites with PD ≥4 mm to those with no site affected was 2.39 (95% CI, 1.32–4.31) among 
participants with serum CRP <1 mg/L. The corresponding estimate was 0.97 (95% CI, 0.57–1.66) for participants with serum CRP levels 
of 1 to 3 mg/L and 1.12 (95% CI, 0.65–1.93) for participants with serum CRP >3 mg/L. Periodontitis was positively associated with higher 
prevalence odds of NAFLD, and this relationship was modified by serum CRP levels.
Keywords: periodontal disease, epidemiology, genetic score, C-reactive protein, inflammatory mediator, hepatic steatosis
Introduction
In response to an injury or infection, inflammation occurs as a 
complex series of short-term adaptive responses accompanied 
by local tissue damage with manifestations that gradually 
resolves as inflammation abates, leaving little to no permanent 
damage (Kumar et al. 2014). Inflammation is regulated primar-
ily by the innate immune system (Takashiba and Naruishi 
2006; Kumar et al. 2014), and it involves a coordinated cas-
cade of biological events regulated by specific cells and molec-
ular signals (Naitza et al. 2012).
An excessive inflammatory response that occurs upon stim-
ulation of the innate immune system has been described as a 
hyperresponsive trait (Shaddox et al. 2010) that presents sys-
temically as a heightened expression of systemic markers of 
inflammation (Southerland et al. 2006). Population-based 
genetic studies suggest that natural selection has shaped the 
evolution of the innate immunity with specific focus on inflam-
matory genes that are pivotal in host-pathogen interactions 
(Barreiro and Quintana-Murci 2010). Inflammatory biomarkers 
are reported to be highly heritable, with studies among ethni-
cally homogeneous groups and twins indicating that about half 
of interindividual variability in markers of inflammation is 
genetically determined (Pankow et al. 2001; Dupuis et al. 
2005). For instance, the Framingham Heart Study reported age- 
and sex-adjusted heritability of 25.3%, 25.4%, and 45.2% for 
C-reactive protein (CRP), interleukin 6 (IL-6), and monocyte
chemoattractant protein 1 (MCP-1), respectively (Dupuis et al.
2005), while the National Heart Lung and Blood Institute
(NHLBI) Family Heart Study reported heritability ranging from 
35% to 40% for CRP, white blood cells, and albumin (Pankow
et al. 2001; Dupuis et al. 2005).
Findings among humans and from mice models (Yoneda 
et al. 2012) suggest a relationship between periodontitis and 
nonalcoholic fatty liver disease (NAFLD), both of which are 
chronic health conditions characterized by a heightened inflam-
matory burden (Day and James 1998; Haukeland et al. 2006; 
Targher 2006; Tilg and Moschen 2010; Schenkein and Loos 
2013; Gocke et al. 2014). Indeed, individuals with periodontitis 
present with frequent bacteremia (Schenkein and Loos 2013) 
that promotes a proinflammatory state, while obesity, a precur-
sor for NAFLD, is characterized by a state of chronic low-grade 
systemic inflammation (Shoelson et al. 2006; Ouchi et al. 2011).
Genome-wide association studies (GWAS) have identified 
19 independent loci that are robustly associated with CRP lev-
els (Dehghan et al. 2011; Naitza et al. 2012), an acute phase 
reactant, and a marker of systemic inflammation (Pearson et al. 
2003; Raman et al. 2013). Because genetic determinants of 
inflammatory biomarkers can more accurately indicate life-
long inflammatory status (Raman et al. 2013) compared to bio-
marker concentrations obtained at a given point in time, 
polymorphisms in genes regulating inflammatory processes 
may influence the expression of periodontitis and NAFLD, as 
well as modify the relationship between these 2 conditions.
The purpose of this investigation was to determine whether 
CRP-associated genetic loci and serum CRP levels modify the 
association between periodontitis and NAFLD.
Methods
Data Source
The Study of Health in Pomerania (SHIP) is a population-
based cohort sampled from the Western Pomeranian region of 
northeastern Germany (John et al. 2001; Volzke et al. 2011). 
The SHIP was designed to provide prevalence estimates for 
various diseases and disease risk factors, incidence of common 
risk factors, subclinical disorders, and clinical diseases and to 
evaluate associations among these factors. From eligible 
inhabitants of West Pomerania in 1996, 6,265 adults aged 20 to 
79 y were invited to participate. A total of 4,308 participated in 
the baseline examination conducted between 1997 and 2001. 
Study participants underwent rigorous examinations, and 
interviewer-administered questionnaires were used to collect 
information on relevant covariates. Ethics approval for this 
study was obtained from the institutional review board of the 
University of North Carolina at Chapel Hill, and this study 
conformed to the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines for reporting 
observational studies.
Exposure Assessment and Definition
Dental examiners performed periodontal examination on study 
participants with no medical contraindication. Measurements 
of probing pocket depth (PD) and clinical attachment level 
(CAL) were obtained on 4 sites per tooth: distobuccal, mesio-
buccal, midbuccal, and midlingual or midpalatal (except the 
third molars) on 2 quadrants (quadrants 1 and 4 or quadrants 2 
and 3). For this investigation, periodontitis was defined as the 
proportion of periodontal sites with PD ≥4 mm categorized as 
none (0%), moderate (<30%), and extensive (≥30%). In a sec-
ondary analysis, periodontitis was investigated as the propor-
tion of sites with CAL ≥3 mm (none, moderate, and extensive) 
and according to the Centers for Disease Control and 
Prevention–American Association for Periodontology (CDC-
AAP) criteria that define severe periodontitis as ≥2 interproxi-
mal sites with CAL of ≥6 mm (not on the same tooth) and ≥1 
interproximal sites with PD of ≥5 mm, and moderate periodon-
titis as ≥2 interproximal sites (not on the same tooth) with CAL 
of ≥4 mm or ≥2 interproximal sites (not on the same tooth) 
with PD of ≥5 mm (Page and Eke 2007). Individuals with mod-
erate or severe periodontitis were categorized as having peri-
odontitis, while participants not meeting these criteria were 
categorized as healthy/mild.
Outcome Assessment and Definition
Trained physicians performed liver ultrasound on study par-
ticipants using a 7.5-MHz transducer (John et al. 2001; Volzke 
et al. 2011). A positive finding on ultrasound was defined as a 
significant increase in liver echogenicity (brightness) relative 
to the kidneys, with the diaphragm indistinct or the echogenic 
walls of the portal veins invisible (Baumeister et al. 2008; 
Williams et al. 2011).
Covariates
Covariates identified as confounders were determined after 
analyzing a directed acyclic graph (Greenland et al. 1999) and 
included age modeled with a quadratic term, sex, alcohol con-
sumption in the past 30 days, and waist circumference, dichot-
omized at ≥88 cm for women and ≥102 cm for men and is 
indicative of abdominal obesity (Grundy et al. 2005). Diabetes 
was based on self-reported physician’s diagnosis or study’s 
measurement of hemoglobin A1c (HbA1c) ≥6.5%. Self-
reported smoking status was categorized as never, former, and 
current. Physical activity was based on self-report of the num-
ber of hours per week of moderate physical activity.
Laboratory Measurements
Nonfasting blood samples were drawn from the cubital vein in 
the supine position. HbA1c was measured by high-performance 
liquid chromatography (ClinRep HbA1C, Recipe Chemicals 
Instruments GmbH), while serum levels of high-sensitivity 
CRP (hs-CRP) were estimated with the Behring Nephelometer 
II (Dade Behring) (Gocke et al. 2014).
Genotyping
Genomic DNA from blood samples was collected using stan-
dardized procedures. Blood aliquots were immediately placed 
on ice after collection and stored at −80°C in a biobank (John 
et al. 2001). A total of 4,096 samples were genotyped using the 
Human SNP 6.0 Array (Affymetrix) with overall genotyping 
efficiency of 98.6% and imputed to the 1000 Genomes v3 ref-
erence panel released March 2012 (ALL ancestries panel, build 
37) (Volzke et al. 2011; Teumer et al. 2013).
A total of 19 CRP single-nucleotide polymorphisms (SNPs)
from 19 loci, 1 IL-6 SNP, 2 MCP-1 SNPs, and 2 erythrocyte 
sedimentation rate (ESR) SNPs were identified as genetic 
markers of inflammation for this investigation. After quality 
control analysis, genotype data were available for 4,070 par-
ticipants. None of the SNPs deviated significantly from Hardy-
Weinberg equilibrium (P > 0.003), and call rates were >95% 
for all SNPs.
CRP-Specific Weighted Genetic Score
To study the cumulative effect of multiple gene loci, a weighted 
genetic score for CRP was computed for each study partici-
pant. A risk allele was defined as the allele associated with a 
unit increase in log-transformed serum CRP level. The corre-
sponding effect sizes from previous GWAS of inflammatory 
mediators (Naitza et al. 2012) and a meta-analysis of GWAS of 
CRP levels (Dehghan et al. 2011) were used to weigh the con-
tribution of each risk allele within the weighted genetic CRP 
score (wGSCRP) as previously described (Pharoah et al. 2008) 
and implemented (Thanassoulis et al. 2012; Xiao et al. 2015). 
The lead SNP in each identified locus were used in creating the 
weighted genetic score. The list of SNPs and effect sizes 
(β estimates) are presented in Appendix Table 1. The weighted 
genetic score for CRP was calculated as follows:
wGS x x x xCRP k k n n= + + +α α α α1 1 2 2  .... ,
where αk is the per-allele β estimate associated with the risk 
allele for CRP SNP k, and Xk is the number of risk alleles for 
the same SNP, and n is total number of SNPs used in creating 
the genetic score. In addition to CRP, weighted genetic scores 
were also created for IL-6, MCP-1, and ESR.
Exclusions
From 4,308 eligible participants at baseline, participants with 
no genotype data (n = 238) were excluded. Also excluded were 
participants who reported excessive alcohol consumption, 
defined as 70 g of ethanol/wk (equivalent to 1 standard drink/
day) for women and 140 g of ethanol/wk (equivalent to 2 stan-
dard drinks/day) for men (n = 970). Participants with no liver 
ultrasound reading (n = 48), as well as those with no periodon-
tal examination (n = 14) or edentulous (n = 563), were also 
excluded. Also excluded were participants with chronic or 
autoimmune viral hepatitis as well as those who self-reported 
use of the following steatosis-promoting medications: tamoxi-
fene, methotrexate, and amiodarone. The resulting analytic 
sample size was 2,481, noting that some participants were 
ineligible for multiple reasons.
Statistical Analysis
The respective genetic scores, including the wGSCRP and log-
transformed serum CRP levels, were modeled as continuous 
traits in separate linear regression models investigating whether 
these traits were associated with periodontitis and NAFLD.
Logistic regression models stratified according to the 
median value for the wGSCRP (<1.98 vs. ≥1.98) assessed the
relationship between periodontitis and NAFLD. In separate 
stratified analyses, a similar association was investigated 
within strata of low (<1 mg/L), intermediate (1 to 3 mg/L), and 
high (>3 mg/L) (Pearson et al. 2003) serum CRP levels. 
Statistical tests were 2-sided, and the test for statistical signifi-
cant interaction was set a priori at P < 0.1. Data analysis was 
conducted in SAS version 9.4 (SAS Institute).
Results
The prevalence of NAFLD was 26.4% (95% confidence inter-
val [CI], 24.6%–28.1%), and 52.7% (95% CI, 50.5%–54.8%) 
had <30% of sites with PD ≥4 mm while 17.8% (95% CI, 
16.0%–19.6%) of the SHIP examinees had ≥30% of sites with 
PD ≥4 mm. Participants with periodontitis (PD ≥4 mm) and 
those with NAFLD had higher serum CRP levels compared to 
their counterparts with a healthy periodontium and without 
NAFLD. The median serum CRPs were 1.48 mg/L (interquar-
tile range [IQR], 0.68–3.01) and 1.82 mg/L (IQR, 0.82–3.90) 
for participants with <30% and ≥30% of sites with PD ≥4 mm, 
respectively, and 1.11 mg/L (IQR, 0.51–
2.95) for participants with no site with PD 
≥4 mm (Table 1). Participants with NAFLD 
were less likely to report physical activity 
(33% vs. 49%), equally as likely to con-
sume alcohol, and more likely to be men 
(58% vs. 41%) than participants without 
NAFLD (Table 1).
Appendix Table 1 shows the full list of 
SNPs with the corresponding effect sizes 
used in creating the respective weighted 
genetic scores. Most of the CRP SNPs were 
positively associated with serum CRP levels 
in this study population (Appendix Fig. 1), 
and the wGSCRP aligns well with serum CRP 
levels such that participants with a low 
genetic CRP score had lower mean serum 
CRP levels compared to participants with a 
high genetic CRP score (Fig. 1). The median 
value for the wGSCRP was 1.98 (IQR, 1.82–
2.14). Participants with wGSCRP above the 
median had a mean (standard deviation 
[SD]) serum CRP of 3.24 (4.72) mg/L, 
while participants with wGSCRP at or below 
the median had a mean (SD) serum CRP of 2.65 (6.62) mg/L.
As expected, serum CRP was associated with periodontitis. 
Specifically, each unit increase in log-transformed serum CRP 
was associated with a 23% increase in adjusted prevalence odds 
of having ≥30% sites with PD ≥4 mm, prevalence odds ratio 
[POR] = 1.23 (95% CI, 1.09–1.39), while the corresponding esti-
mate for having <30% of sites with PD ≥4 mm was POR = 1.16 
(95% CI, 1.06–1.26) (Table 2). There was no meaningful associa-
tion between individual CRP SNPs and periodontitis (Appendix 
Figs. 2–4). Even after combining into a score, the wGSCRP was 
not associated with the prevalence odds of having <30% sites or 
≥30% sites with PD ≥4 mm, POR = 1.02 (95% CI, 0.69–1.51) 
and 1.01 (95% CI, 0.61–1.69), respectively (Table 2).
As was observed for periodontitis, each unit increase in log-
transformed serum CRP was associated with a higher preva-
lence odds of NAFLD, with adjusted POR = 1.26 (95% CI, 
1.14–1.39) (Table 2). Likewise, most of the individual CRP 
SNPs had no meaningful effect on the prevalence odds of 
Table 1. Distribution of Baseline Factors According to the Proportion of Sites with PD ≥4 mm and Nonalcoholic Fatty Liver Disease Status among 
Participants of the Study of Health in Pomerania, 1997 to 2001.













CRP, mg/L 1.42 (0.64, 3.01) 1.11 (0.51, 2.95) 1.48 (0.68, 3.01) 1.82 (0.82, 3.90) 1.20 (0.55, 2.95) 2.16 (0.99, 4.41)
Age, y 47.0 (34.0, 60.0) 36.0 (27.0, 56.0) 47.0 (35.0, 60.0) 55.0 (46.0, 65.0) 42.0 (31.0, 57.0) 56.0 (46.0, 65.0)
Waist circumference, cm 88.0 (77.2, 98.1) 83.0 (73.0, 94.0) 89.0 (78.0, 98.0) 94.0 (84.5, 103) 84.0 (74.3, 93.8) 98.5 (90.8, 106)
Alcohola 4.10 (1.31, 6.86) 4.56 (1.39, 6.71) 4.09 (1.31, 7.17) 3.92 (0.65, 6.41) 4.08 (1.31, 6.86) 4.28 (0.83, 6.86)
Abdominal obesityb 747 (30.1) 170 (23.2) 389 (29.8) 188 (42.6) 383 (21.0) 364 (55.7)
Physical activity 1,099 (44.5) 388 (53.0) 586 (45.0) 125 (28.5) 881 (48.5) 218 (33.3)
Men 1,116 (45.0) 281 (38.3) 592 (45.3) 243 (55.1) 740 (40.5) 376 (57.5)
Smoking
 Never 966 (39.1) 323 (44.1) 515 (39.6) 128 (29.2) 717 (39.4) 249 (38.1)
 Former 780 (31.6) 203 (27.7) 434 (33.4) 143 (32.7) 527 (29.0) 253 (38.7)
 Current 726 (29.4) 207 (28.2) 352 (27.1) 167 (38.1) 574 (31.6) 152 (23.2)
Diabetes mellitus 465 (18.7) 98 (13.4) 248 (19.0) 119 (27.0) 226 (12.4) 239 (36.5)
NAFLD 654 (26.4) 133 (18.1) 348 (26.6) 173 (39.2) — —
Data are presented as No. (%) or median (lower quartile, upper quartile).
CDC-AAP, Centers for Disease Control and Prevention–American Academy of Periodontology; CRP, C-reactive protein; NAFLD, nonalcoholic fatty
liver disease; PD, pocket depth.
aAverage number of standard drinks in the past 30 days.
bSex-specific weight circumference defined as ≥88 cm for women and ≥102 cm for men (Grundy et al. 2005).
Figure 1. Mean serum C-reactive protein (CPR) levels (right vertical axis) shown as solid 
black line for categories of the weighted genetic CRP score. The shaded bars show the 
distribution of the weighted CRP score in the study population (left vertical axis). hs, high 
sensitivity.
NAFLD (Appendix Fig. 5), while each unit increase in the 
wGSCRP was associated with a 21% increase in the prevalence 
odds of NAFLD; POR = 1.21 (95% CI, 0.82–1.78) (Table 2).
Although participants with periodontitis had a higher pre-
dicted probability of NAFLD compared to participants with a 
healthy periodontium, there was no significant statistical inter-
action (i.e., effect measure modification on the multiplicative 
scale) according to tertile of the wGSCRP (Pinteraction = 0.8) (Fig. 
2A). Despite this, estimates stratified at the median value for 
wGSCRP are presented in Table 3. Participants in the stratum of 
wGSCRP at or below the median had slightly lower unadjusted 
and covariate-adjusted prevalence odd ratios for the relation-
ship between periodontitis (PD ≥4 mm) and NAFLD compared to 
participants in the wGSCRP stratum above the median (Table 3).
In contrast, the higher predicted 
probability of NAFLD for participants 
with periodontitis (PD ≥4 mm) differed 
according to serum CRP levels 
(Pinteraction = 0.01) (Fig. 2B). And in con-
trast to the wGSCRP, stratified analyses 
show a magnitude of unadjusted and 
covariate-adjusted prevalence odds of 
NAFLD comparing participants with 
periodontitis to those without to be 
highest in the low serum CRP (CRP <1 
mg/L) stratum. For instance, the unad-
justed and covariate-adjusted NAFLD 
prevalence odds ratio comparing par-
ticipants with ≥30% sites with PD ≥4 
mm to those with no sites affected in 
the low-serum CRP (<1 mg/L) stratum were 5.34 (95% CI, 
3.18–8.97) and 2.39 (95% CI, 1.32–4.31), respectively, while 
the corresponding estimates for participants in the high-serum 
CRP (>3 mg/L) stratum were 1.66 (95% CI, 1.04–2.65) and 
1.12 (95% CI, 0.65–1.93), respectively (Table 3).
Contrary to the finding of a significant statistical interaction 
between serum CRP and PD ≥4 mm, there was no significant 
interaction with CAL ≥3 mm (Pinteraction = 0.2). This suggests 
that the significant interaction observed with the CDC-AAP 
periodontitis classification (Pinteraction = 0.014) appeared to have 
been driven mostly by PD instead of CAL. Stratified estimates 
for periodontitis defined as the proportion of sites with CAL 
≥3 mm and based on the CDC-AAP criteria are presented in 
Appendix Tables 2 and 3, respectively.
Table 2. Association between Serum CRP and Genetic Determinants of Inflammatory Mediators with Proportion of Sites with PD ≥4 mm and 
NAFLD in the Study of Health in Pomerania, 1997 to 2001.
Prevalence Odds Ratio (95% CI) for the Proportion of 
Sites with PD ≥4 mm (Reference = 0%) Prevalence Odds Ratio (95% CI) for NAFLD
PD ≥4 mm Crude Adjusteda Crude Adjusteda
Serum CRPb
<30% 1.19 (1.10–1.29) 1.16 (1.06–1.26) 1.49 (1.37–1.61) 1.26 (1.14–1.39)
≥30% 1.40 (1.26–1.56) 1.23 (1.09–1.39)
Genetic scoresb
 wGSCRP
  <30% 1.02 (0.69–1.51) 1.21 (0.82–1.78)
  ≥30% 1.01 (0.61–1.69)
 wGSIL-6
  <30% 0.83 (0.49–1.40) 0.54 (0.32–0.90)
  ≥30% 0.60 (0.31–1.19)
 wGSESR
  <30% 1.24 (0.53–2.91) 1.61 (0.69–3.76)
  ≥30% 0.99 (0.33–3.04)
 wGSMCP
  <30% 0.88 (0.60 1.29) 1.07 (0.73–1.57)
  ≥30% 1.09 (0.66–1.80)
CI, confidence interval; CRP, C-reactive protein; NAFLD, nonalcoholic fatty liver disease; PD, pocket depth; wGSCRP, weighted genetic CRP score; 
wGSESR, weighted genetic erythrocyte sedimentation rate score; wGSIL-6, weighted genetic interleukin 6 score; wGSMCP, weighted genetic monocyte 
chemoattractant protein score.
aAdjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption, and diabetes.
bEstimate is for each unit increase in the respective genetic scores or log-transformed CRP.
Figure 2. Predicted probability of nonalcoholic fatty liver disease (NAFLD) according to tertile of 
the weighted genetic C-reactive protein (CRP) score (A) and categories of serum CRP (B) for study 
participants with no site (square), <30% of sites (circle), and ≥30% of sites (diamond) with pocket 
depth ≥4 mm.
Discussion
Findings from this investigation aimed at assessing whether 
inflammatory burden of which CRP was used as a marker 
modified the relationship between periodontitis and NAFLD, 
were consistent with a positive association between serum 
CRP and NAFLD as well as serum CRP and periodontitis. 
Under the premise that genetic determinants of inflammatory 
markers are better able to indicate lifelong inflammatory sta-
tus, genetic variants robustly associated with CRP levels were 
combined into a genetic score that was substituted for serum 
CRP in this study. Contrary to the findings for serum CRP, the 
wGSCRP predicted NAFLD to a greater extent than it did for 
periodontitis. And while serum CRP was a significant modi-
fier, the wGSCRP was not a modifier of the association between 
periodontitis and NAFLD.
NAFLD has a multifactorial etiology with conditions like 
insulin resistance and obesity identified as risk factors (Farrell 
and Larter 2006; Angulo 2007). Increased levels of inflamma-
tory mediators have also been reported in individuals with 
NAFLD (Haukeland et al. 2006; Targher 2006). While a formal 
mediation analysis was beyond the scope of this study because 
of its cross-sectional nature, investigating the periodontitis-
NAFLD association conditioning on or stratifying by markers 
of inflammatory burden while adjusting for confounders and 
NAFLD risk factors offers insights into the potential role of 
other factors besides inflammation in NAFLD etiology.
Despite the high CRP heritability (Pankow et al. 2001; 
Dupuis et al. 2005), currently identified genetic loci explain 
~5% of the variation in serum CRP levels (Dehghan et al. 
2011). Thus, currently identified loci may not be sufficiently 
robust to characterize associations or detect gene-environment 
interactions, even after combining the lead SNPs into a score 
as was done in this study. This may in part explain why no 
significant effect measure modification within strata of the 
genetic CRP score was detected.
Serum CRP represents a systemic marker of an inflamma-
tory response and can be instrumental in detecting effect mea-
sure modification. The associations between periodontitis and 
NAFLD within levels of serum CRP were contrary to expecta-
tion. Indeed, the greater magnitude of association in the stra-
tum of serum CRP <1 mg/L suggests a contribution of 
periodontitis to NAFLD burden independent of chronic low-
grade systemic inflammation. This association may have been 
induced via pathways involving an alteration in the gut micro-
bial composition by swallowed periodontal pathogens 
(Arimatsu et al. 2014). Furthermore, participants with serum 
CRP <1 mg/L were less likely to have established NAFLD risk 
factors like abdominal obesity and diabetes (Appendix Table 
4), consistent with an association of periodontitis with NAFLD 
independent of these factors.
While periodontitis may also contribute to NAFLD burden 
in the intermediate- and high-serum CRP strata, these associa-
tions in opposite of expectation suggest that the effects of peri-
odontitis on NAFLD may be conditioned by a systemic 
inflammatory response of which CRP is a marker. Alternatively, 
the higher levels of serum CRP may indicate the presence to a 
larger extent of competing risk factors for NAFLD (Appendix 
Table 3. Stratified Analysis for the Association between the Proportion of Periodontal Sites with Pocket Depth ≥4 mm (0%, <30%, ≥30%) and 
NAFLD According to Categories of the Weighted Genetic CRP Score and Serum CRP Levels, in the Study of Health in Pomerania, 1997 to 2001.
NAFLD, n Prevalence Odds Ratio (95% CI)
Cases Noncases Crude Adjusteda
wGSCRP ≤1.98 (n = 1,222)
No site (0%) 65 292 Reference Reference
Moderate (<30%) 166 479 1.56 (1.13–2.15) 1.08 (0.75–1.57)
Extensive (≥30%) 81 139 2.62 (1.78–3.84) 1.14 (0.72–1.80)
wGSCRP >1.98 (n = 1,259)
No site (0%) 68 308 Reference Reference
Moderate (<30%) 182 480 1.72 (1.26–2.35) 1.33 (0.94–1.89)
Extensive (≥30%) 92 129 3.23 (2.22–4.70) 1.65 (1.07–2.55)
Serum CRP <1 mg/L (n = 972)
No site (0%) 29 313 Reference Reference
Moderate (<30%) 89 402 2.40 (1.53–3.73) 1.62 (1.00–2.61)
Extensive (≥30%) 46 93 5.34 (3.18–8.97) 2.39 (1.32–4.31)
Serum CRP 1 to 3 mg/L (n = 887)
No site (0%) 48 190 Reference Reference
Moderate (<30%) 151 337 1.77 (1.23–2.57) 1.37 (0.90–2.08)
Extensive (≥30%) 58 103 2.23 (1.42–3.50) 0.97 (0.57–1.66)
Serum CRP >3 mg/L (n = 622)
No site (0%) 56 97 Reference Reference
Moderate (<30%) 108 220 0.85 (0.57–1.27) 0.70 (0.45–1.10)
Extensive (≥30%) 69 72 1.66 (1.04–2.65) 1.12 (0.65–1.93)
Interaction P value for the genetic CRP score = 0.6. Interaction P value for serum CRP levels = 0.01. CI, confidence interval; CRP, C-reactive protein; 
NAFLD, nonalcoholic fatty liver disease; wGSCRP, weighted genetic score for CRP.
aAdjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption, and diabetes.
Table 4), whose effects likely overshadowed those of periodon-
titis. Last, it is also possible that the high CRP levels may have 
been generated in response to hepatic injury as a result of NAFLD.
In theory, polymorphisms robustly associated with serum 
CRP levels are expected to predict an increase in the risk of 
coronary heart disease (CHD) and other cardiovascular 
disease–related events. However, these polymorphisms are not 
associated with an increased risk of CHD (Zacho et al. 2008; 
Elliott et al. 2009; Dehghan et al. 2011; Wensley et al. 2011), 
while serum CRP levels have been reported in several longitu-
dinal studies to be associated with increased risk of CHD and 
myocardial infarction (Danesh et al. 2004; Lange et al. 2006). 
The SNPs used in creating the genetic CRP score in this study 
were robustly associated with CRP levels (Appendix Fig. 1), 
but these SNPs did not independently predict periodontitis or 
NAFLD risk (Appendix Figs. 2–5). While the findings for the 
genetic CRP score are not entirely surprising, it is also likely 
that the inability to detect effect measure modification by the 
genetic CRP score was also due to the relatively small effect of 
the individual SNPs even after combining them into a score.
Strengths and Limitations
Given the modest size, this study may be insufficiently pow-
ered to detect effect measure modification, especially for the 
genetic CRP score. In addition, the cross-sectional design 
makes it difficult to infer how the modification by serum CRP 
levels might affect the periodontitis-NAFLD association over 
time. Last, due to the mostly homogeneous study population, 
findings may not generalize to other racial/ethnic groups espe-
cially given that the genetic architecture of CRP differs by eth-
nicity (Carlson et al. 2005). Study strengths include a good 
characterization of the cohort that enabled the implementation 
of relevant exclusions of factors like alcohol consumption that 
might bias findings if not accounted for. Also, the availability 
of genotype and phenotype data for CRP allowed an investiga-
tion of this factor as a potential effect measure modifier.
Conclusion
Serum CRP was a significant modifier of the relationship 
between periodontitis and NAFLD, and there was a discor-
dance of effect measure modification of this association by 
serum CRP and the weighted CRP genetic score. Given that 
only a fraction of the variability in CRP is explained by cur-
rently identified genetic loci, more research may be needed to 
identify missing CRP heritability that could provide a more 
robust picture of genetic loci predictive of CRP levels and 
inflammatory markers in general.
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